DUAKLIR PRESSAIR (aclidinium bromide and formoterol fumarate) provides LAMA/LABA therapy.
David Frabotta
Advertisement
Articles by David Frabotta
Approved regulations allow for some flexibility for drugs that can be redistributed or qualify for manufacturer credit.
Erdafitinib is first targeted therapy for FGFR3 or FGFR2 genetic alteration.
Health systems employ Artifical Intelligence and integrated medication management to address diversion.
Advertisement
Latest Updated Articles
BD Unveils New Tool to Fight Opioid CrisisPublished: December 17th 2018 | Updated:
Balversa Fast-Tracked for Bladder CancerPublished: April 12th 2019 | Updated:
EPA’s New Rules on Drug Disposal Begin in AugustPublished: April 17th 2019 | Updated:
FDA Approves New COPD Maintenance TreatmentPublished: April 24th 2019 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Finerenone in HFpEF and HFmrEF: Emerging Evidence and Guideline Updates
2
American Pharmacists Month: Technology Transforms Pharmacy Practice, Demands New Skills
3
Pharmacists Improve Diabetes Outcomes Through Continuous Glucose Monitoring Services
4
American Pharmacists Month: Evolution of Experiential Learning for Pharmacy Students
5
